Related Experiment Video
Updated: Jun 16, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Phosphate elimination in modalities of hemodialysis and peritoneal dialysis
1Department of Internal Medicine - Nephrology, Vivantes Klinikum im Friedrichshain, Berlin, Germany. martin.kuhlmann@vivantes.de
Insights
Hyperphosphatemia management in dialysis patients is crucial for reducing cardiovascular risk. Optimizing dialysis strategies, like hemodiafiltration or extended treatments, improves phosphate removal, potentially reducing medication needs.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Renal Replacement Therapy
Background:
- Hyperphosphatemia is common in hemodialysis (HD) and peritoneal dialysis (PD) patients.
- It significantly increases cardiovascular mortality risk.
- Phosphate elimination via dialysis is key to managing this condition.
Purpose of the Study:
- To review factors influencing phosphate clearance in HD and PD.
- To discuss strategies for enhancing phosphate mass removal.
- To guide optimal dialysis modality selection for hyperphosphatemic patients.
Main Methods:
- Analysis of factors affecting phosphate clearance in HD prescription (e.g., flow rates, membrane surface area, ultrafiltration).
- Evaluation of enhanced dialysis techniques like hemodiafiltration, increased frequency, and extended treatment times.
- Assessment of phosphate removal correlation with peritoneal creatinine and urea clearance in PD.
Main Results:
- Phosphate clearance in HD is influenced by dialysis prescription parameters.
- Hemodiafiltration, higher frequency, and extended dialysis times improve phosphate mass removal.
- In PD, phosphate removal correlates with peritoneal creatinine clearance, not urea clearance.
Conclusions:
- Optimized HD strategies, including short daily, extended daily, or nocturnal HD, enhance phosphate removal and may reduce phosphate binder use.
- PD modality selection for hyperphosphatemic patients should consider peritoneal creatinine and phosphate transport characteristics.
Abstract:
Hyperphosphatemia is highly prevalent in hemodialysis (HD) and peritoneal dialysis (PD) patients and is a major risk factor for cardiovascular mortality. Elimination of inorganic phosphate by dialysis is a cornerstone of the management of hyperphosphatemia. Phosphate clearance during HD is affected by various factors of dialysis prescription, such as blood and dialysate flow rate, dialyzer membrane surface area and ultrafiltration volume. Phosphate mass removal can be improved by hemodiafiltration, increased dialysis frequencies and extended treatment times. Short daily or extended daily or 3 times weekly nocturnal HD allow higher phosphate mass removal and potentially complete discontinuation of phosphate binder medication. In PD, phosphate mass removal appears to be correlated with peritoneal creatinine but not urea clearance. In hyperphosphatemic PD patients, the decision on the optimal PD modality should be based on peritoneal creatinine and ideally also on peritoneal phosphate transport characteristics.
Related Concept Videos
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Peritoneal Dialysis I: Introduction and Procedure
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis III: Nursing Management
Hemodialysis III: Nursing Management
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
